Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0000950170-25-093852)

Filing Details

Accession Number:: 0000950170-25-093852
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-07-03 16:11:49
Reporting Period:: 2025-07-01

Filing Date:: 2025-07-03
Accepted Time:: 2025-07-03 16:11:49
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1652130	Intellia Therapeutics Inc.	NTLA	In Vitro & In Vivo Diagnostic Substances (2835)	364785571

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1914448	Eliana Clark	C/O Intellia Therapeutics, Inc. 40 Erie Street; Suite 130 Cambridge MA 02139	Evp, Chief Technical Officer	No	No	No	No

Transaction Summary

Sold:	1,022 shares	Avg. Price: $9.82	Total Value: $10,036.04
Number of Shares After Transactions:	95,369 shares

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-07-01	1,022	$9.82	95,369	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

Sale of 1,022 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025.